北海康成启动高瑞宁北非市场注册及商业准备

1
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take
no responsibility for the contents of this announcement, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this announcement.
CANbridge Pharmaceuticals Inc.
ʮ̡
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1228)
VOLUNTARY ANNOUNCEMENT
EXPANSION OF GAURUNNING ® (VELAGLUCERASE-BETA FOR
INJECTION) INTO NORTH AFRICAN MARKET
This announcement is made by CANbridge Pharmaceuticals Inc. (the “ Company ”, together with its
subsidiaries, the “Group”) on a voluntary basis to update the shareholders and potential investors of the
Company on the latest business development of the Group in relation to the expansion of Gaurunning ®
(velaglucerase-beta for injection) (“Gaurunning”) into the North African market.
The board of directors (the “Board”) of the Company is pleased to announce that the Group has fully
initiated the registration procedures and commercial readiness work for Gaurunning to cover a key North
African market, and launch preparations in the region have commenced. The Group’s entry into the
North African market, a region with sizable market potential and unmet clinical needs, marks the first
step for Gaurunning to expand into a growing global Gaucher disease market.
Gaurunning has been granted marketing approval by the National Medical Products Administration (the
“NMPA”) of the People’s Republic of China (the “PRC”) on May 15, 2025 and is the first domestically
independently developed long-term enzyme replacement therapy approved in the PRC for adolescents
aged 12 and above and adults with Type I and Type III Gaucher disease. Gaurunning is the Company’s
first in-house developed enzyme replacement therapy, and the Company holds global proprietary rights
to develop and commercialize Gaurunning. As an innovative biologic drug, Gaurunning is positioned
as an alternative to comparable imported products. The expected lower treatment costs will enhance
treatment accessibility and sustainability for Gaucher disease patients globally. In addition, an NMPA-
approved registration trial is ongoing, aiming to expand Gaurunning’s label to patients aged 2 to under
12.
The Company considers that the expansion of Gaurunning into the North African market represents an
important milestone for the international rollout of Gaurunning into the global Gaucher disease market.
Such expansion is expected to not only enhance treatment accessibility for Gaucher disease patients in
North Africa, but also diversify the Group’s revenue mix, strengthen its profit base and deliver long-
term value to shareholders over the medium to long term.

2
As at the date of this announcement, the Group is progressing with the registration procedures and
commercial readiness work as mentioned above, and no formal sales revenue has yet been derived
from the North African market in respect of Gaurunning. The completion of the applicable registration
procedures with the relevant health authorities remains subject to, among other things, review and
approval by such authorities. Shareholders and potential investors of the Company are advised to
exercise caution when dealing in the shares of the Company.
By Order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman
Hong Kong, July 30, 2026
As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director;
Ms. Wei Zhao and Mr. Tingwei Wang as non-executive Directors; and Dr. Richard James Gregory,
Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive
Directors.